Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...
On Friday, Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (NASDAQ:SNY) stock from Sell to Hold and increased the price target to €100.00 from €85.00. The adjustment ...
On Friday, Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (EPA:SASY) (NASDAQ:SNY) stock from Sell to Hold and increased the price target to €100.00 from €85.00. The adjustment ...
Citigroup Inc. and UBS Group AG are organizing about €2 billion ($2.1 billion) of funding to back Bain Capital’s acquisition of German facility-management company Apleona Group GmbH — a rare deal amid ...
EU exports to the US reached $605.8 billion in 2024, according to the US Census Bureau. Pharmaceutical companies are particularly vulnerable, according to BI strategists Laurent Douillet and Kaidi ...
Co-authors reported receiving personal fees from Baxter, Getinge, Inspira, and Vasomune; a consulting agreement with Vertex and Sanofi for clinical ... Robinson CH, et al "Comparative efficacy ...
Dupixent sales surpassed the 13 billion euro target, growing by 23%. Sanofi announced a 5 billion euro share buyback for 2025. The company proposed a 3.92 euro dividend per share, marking the 30th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback